908 Devices Announces Pricing of Initial Public Offering

Rhea-AI Summary

908 Devices announced the pricing of its upsized initial public offering (IPO) of 6,500,000 common stock shares at $20.00 each, aiming to raise $130 million gross proceeds. The underwriters have a 30-day option to purchase an additional 975,000 shares. Trading is set to begin on Nasdaq under the symbol 'MASS' on December 18, 2020, with the offering expected to close on December 22, 2020. Cowen and SVB Leerink are the lead book-running managers for the offering. The company specializes in handheld and desktop mass spectrometry devices for critical applications in various sectors.

Positive

• Successful pricing of IPO at $20.00 per share, potentially raising $130 million.
• Upsized offering indicates strong investor interest, which may enhance market confidence.
• The company's innovative mass spectrometry devices target critical sectors like life sciences and forensics.

Negative

• Dilution of existing shareholders with the introduction of new shares.
• Market reaction to IPO pricing could impact the stock's initial trading performance.

908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of its upsized initial public offering of shares of its common stock, with 6,500,000 shares being offered by the Company at a public offering price of $20.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 975,000 shares of common stock from the Company at the public offering price. The shares are expected to begin trading on the Nasdaq Global Market on December 18, 2020 under the ticker symbol “MASS.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by 908 Devices are expected to be $130.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 22, 2020, subject to the satisfaction of customary closing conditions.

Cowen and SVB Leerink acted as lead book-running managers for the proposed offering. William Blair and Stifel acted as book-running managers for the proposed offering.

A registration statement on Form S-1 relating to the shares sold in the initial public offering has been filed with the Securities and Exchange Commission and became effective on December 17, 2020. The offering will be made only by means of a prospectus, copies of which may be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02120, telephone: 1-800-808-7525, ext. 6132, or by email at syndicate@svbleerink.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About 908 Devices

908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it conducts research, designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.

Forward Looking Statements

This press release includes “forward looking information,” including with respect to the timing of the initial public offering and our intended use of proceeds. Words or phrases such as “will,” “believes,” “intends” or “expects” or similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions, including the risks outlined under “Risk Factors” in the preliminary prospectus and elsewhere in the Company’s filings with the SEC, which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006224/en/

FAQ

What is the stock symbol for 908 Devices?

The stock symbol for 908 Devices is 'MASS'.

When will 908 Devices start trading on Nasdaq?

908 Devices is expected to start trading on Nasdaq on December 18, 2020.

How much money is 908 Devices aiming to raise with its IPO?

908 Devices aims to raise approximately $130 million through its IPO.

What is the offering price for 908 Devices' shares?

The offering price for 908 Devices' shares is $20.00 each.

Who are the underwriters for the 908 Devices IPO?

Cowen and SVB Leerink are the lead book-running managers for the 908 Devices IPO.